Vascular Flow Technologies has reported positive results from a study, which showed 30% increase in one-year success for infrainguinal vascular bypass surgery in patients who received a Spiral Flow Graft.
The increase is evident through a comparision to those who received a standard polytetrafluoroethylene (PTFE) graft.
Bradford Royal Infirmary vascular surgeon consultant Nick Shaper, who led the study showed one-year primary and secondary patency rates of 76% and 87% for Spiral Flow Grafts, compared to 48% and 55% for PTFE bridge graft.
The study also revealed a lower amputation rate in patients receiving Spiral Flow Grafts.
Mr Shaper said: "All patients demonstrated post-operative spiral laminar flow at the distal anastomosis, and there was a substantial and highly encouraging improvement in one-year patency rates in this group of patients."
Vascular Flow Technologies’s Spiral Laminar Flow (SLF) technology restores the blood flow pattern through prosthetic grafts to the body’s natural state, spiral flow.
The technology platform is based on a renewed understanding of natural blood flow patterns in the body.
SLF technology is proven to replicate natural blood flow by generating a spiral laminar flow within the graft, reducing turbulence at the point where the blood flows into the blood vessel.
The data will add to a growing body of evidence showing improved clinical outcomes for patients who receive a Spiral Flow Graft.
The newly opened Spiral Flow arteriovenous (AV) Access Graft clinical registry will collect the primary, primary assisted and secondary patency rates of the Spiral Flow AV Access Graft in patients with end-stage renal disease (ESRD) as well as recording complication rates.
Vascular Flow Technologies CEO Bill Allan said: "Clinical experience with Spiral Flow Grafts is continuing to grow, and the newly opened US registry will provide a further bank of data for evaluation of long-term patency and complication rates.
"We are encouraging haemodialysis physicians to view the portal and to seek Institutional Review Board (IRB) approval to start entering patient data."